587
Participants
Start Date
February 17, 2009
Primary Completion Date
November 15, 2011
Study Completion Date
August 25, 2017
Brivanib
Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
Placebo
Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
Best Supportive Care
Trans-Arterial Chemo-Embolization (TACE) Therapy
Local Institution, Taipei
Local Institution, Taipei
Local Institution, Taoyuan Hsien
Local Institution, Taichung
Local Institution, Tainan City
Local Institution, Brussels
Local Institution, Rosario
Local Institution, Hong Kong
Mount Sinai School Of Medicine, New York
Columbia University Medical Center, New York
Local Institution, Berlin
Local Institution, D.f.
Local Institution, Kifissia
University Of Pennsylvania, Philadelphia
Local Institution, Milan
Local Institution, Milan
Mcguire Dvamc, Richmond
Local Institution, Madrid
Local Institution, Tianjin
Local Institution, Hanover
Local Institution, Toulouse
UF Health Clinical Research Center, Gainesville
Local Institution, Oviedo
Local Institution, Bordeaux
Local Institution, Montpellier
Local Institution, Montpellier
Local Institution, Rennes
Local Institution, Padua
Local Institution, Grenoble
James Graham Brown Cancer Center, Louisville
Ohio State University, Columbus
Local Institution, Meldola (fc)
3912 Taubman Center, Ann Arbor
Henry Ford Health System Irb, Detroit
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Thessaloniki
Local Institution, Mainz
Mayo Clinic, Rochester
Local Institution, Pisa
Local Institution, Lille
Local Institution, Ancona
Local Institution, Frankfurt
Local Institution, Cuernavaca
Local Institution, Lyon
Univ Of Ark For Med Sci, Little Rock
Local Institution, Paris
Local Institution, Paris
Local Institution, Paris
University Of Texas, Houston
The University Of Texas Health Science Center, San Antonio
Local Institution, Freiburg im Breisgau
Local Institution, Napoli
Mayo Clinic Arizona, Scottsdale
Local Institution, Ulm
Sharp Clinical Oncology Research, San Diego
Loma Linda University Cancer Center, Loma Linda
Local Institution, Créteil
Pacific Hematology Oncology Associates, San Francisco
Local Institution, Villejuif
Local Institution, Würzburg
Oregon Health & Sci Univ, Portland
Local Institution, Beijing
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Hangzhou
Local Institution, Nanjing
Local Institution, Wuhan
Local Institution, Guangzhou
Local Institution, Nanning
Local Institution, Chennai
Local Institution, Busan
Local Institution, Guanzhou
Local Institution, Kochi
Local Institution, Bunkyo-ku
Local Institution, Musashino-shi
Local Institution, Chiba
Local Institution, Kashiwa-shi
Local Institution, Sunto-gun
Local Institution, Ogaki-shi
Local Institution, Tsu
Local Institution, Higashinari-ku
Local Institution, Osaka
Local Institution, Osaka
Local Institution, Osaka-sayama-shi
Local Institution, Kyoto
Local Institution, Nishinomiya-shi
Local Institution, Shimonoseki-shi
Local Institution, Kochi
Local Institution, Toyama
Richard Finn, M.D., Los Angeles
Local Institution, Capital Federal
Local Institution, Salvador
Local Institution, Salvador - Ba
Local Institution, Porto Alegre
Local Institution, São Paulo
Local Institution, Calgary
Local Institution, Vancouver
Local Institution, Toronto
Local Institution, Halle
Local Institution, Kolkata
Local Institution, New Delhi
Local Institution, Yokohama
Local Institution, Chuo-ku
Local Institution, Toluca
Local Institution, San Juan
Local Institution, Daegu
Local Institution, Gyeonggi-do
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY